CurePSP Expands Care Network to Europe

NEW YORK, Sept. 22, 2026 /CourierPR/ -- CurePSP, the leading nonprofit organization dedicated to the awareness, care and cure for three neurodegenerative diseases: progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA), has expanded its prestigious Center of Care network beyond North America for the first time since its founding in 2017. The program has grown to 44 institutions across five countries, with the addition of eight new centers: Stony Brook University, the University of Virginia, Washington University in St. Louis, Yale University, University of Texas Southwestern, Hospital Clínic de Barcelona, Ludwig-Maximilians-University (LMU) Munich, and the National Hospital for Neurology and Neurosurgery, Queen Square.

The new centers bring fresh perspectives to CurePSP's work and extend its reach into new regions and communities, including for the first time, Europe. The foundational program advances regional and global leadership in comprehensive care delivery and innovative research for the neurodegenerative diseases of progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA). For people living with these rare, quickly progressive diseases, access to specialized care can be the difference between years of misdiagnosis and a treatment plan that addresses their specific needs.

CurePSP, a nonprofit organization dedicated to the awareness, care, and cure for three neurodegenerative diseases: progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA), has expanded its Center of Care network to include eight new institutions in Europe, bringing the total to 44 centers across five countries. The new centers, which include Stony Brook University, the University of Virginia, Washington University in St. Louis, Yale University, University of Texas Southwestern, Hospital Clínic de Barcelona, Ludwig-Maximilians-University (LMU) Munich, and the National Hospital for Neurology and Neurosurgery, Queen Square, bring fresh perspectives to CurePSP's work and extend its reach into new regions and communities, including Europe for the first time. The program, which has grown to 44 institutions since its founding in 2017, advances regional and global leadership in comprehensive care delivery and innovative research for the neurodegenerative diseases of progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA). For people living with these rare, quickly progressive diseases, access to specialized care can be the difference between years of misdiagnosis and a treatment plan that addresses their specific needs. CurePSP, a registered 501(c)(3) charity within the United States (EIN: 52-1704978), requires the new centers to reapply for designation every three years. For more information and a complete listing of CurePSP Centers of Care, visit www.psp.org/centers-of-care.